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ABSTRACT 
 
We have established a uniform procedure for the expression and purification of the cyclin-dependent kinases CDK7/CycH/MAT1, 
CDK8/CycC and CDK9/CycT1. We attach a His6-tag to one of the subunits of each complex and then co-express it together with the 
other subunits in Spodoptera frugiperda insect cells. The CDK complexes are subsequently purified by Ni2+-NTA and Mono S 
chromatography. This approach generates large amounts of active recombinant kinases that are devoid of contaminating kinase activities. 
Importantly, the properties of these recombinant kinases are similar to their natural counterparts (Pinhero et al. 2004, Eur J Biochem 
271:1004-14). Our protocol provides a novel systematic approach for the purification of these three (and possibly other) recombinant 
CDKs. 
 
 
INTRODUCTION 
 
Cyclin-dependent kinases (CDKs) play important roles in the 
regulation of eukaryotic cell cycle and gene expression. They 
represent a family of Ser/Thr protein kinases that are critically 
dependent on their association with a cyclin partner (1). In addition, 
these kinases are regulated by a variety of mechanisms including 
phosphorylation events, association with inhibitory proteins and 
assembly factors, and protein degradation (1). 
 
Three CDKs (CDK7, CDK8 and CDK9) have been implicated in 
the phosphorylation of the carboxyl-terminal domain (CTD) of the 
largest subunit of RNA polymerase II (RNA pol II) (2, 3). The 
phosphorylation of this domain is essential for several post-
initiation events during the synthesis of mRNA in all eukaryotes (2, 
3). It is important that CDK7, CDK8 and CDK9 are biochemically 
and functionally distinct kinases (4, 5) that execute non-redundant 
functions during the transcription reaction (2). CDK7 exists in 
several forms including a core tri-partite CDK7/CycH/MAT1 
complex known as CAK (cyclin-dependent kinase activating 
kinase), as a component in the general transcription factor TFIIH 
and as a component of larger complexes containing pol II and other 
transcription factors (2). CDK8/CycC exists as a bipartite complex, 
but has also been found in a variety of complexes that contain pol 
II and general pol II transcription factors (2). CDK9 was initially 
identified as P-TEFb (Positive Transcription Elongation Factor-b) 
(6). Independently, CDK9/CycT1 has been isolated as the HIV-tat 
associated kinase TAK (7). 
 
CDK7/CycH/MAT1 acts as a cyclin-dependent kinase activating 
kinase that phosphorylates and activates different CDKs in Xenopus 
and mammalian extracts (8). As a component of the general 
transcription factor TFIIH, this complex also phosphorylates the Pinhero et al.    
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carboxyl-terminal domain of pol II. The retinoic acid receptors 
(RAR)-α-1 and (RAR)-γ (9, 10), the estrogen receptor-α (11), the 
transactivator Oct-1 (12) and the tumor suppressor p53 (13) have 
also been identified as  substrates of CDK7. The substrate 
preferences of CDK8/CycC and CDK9/CycT1 have not been 
extensively characterized. 
 
All of the previous studies on CDK7, CDK8 and CDK9 were 
carried out with kinases that were immunoprecipitated from cell 
extracts or by epitope-tagged recombinant kinases that were 
purified by analytical scale affinity schemes (for references see (14)). 
In many cases, the homogeneity of the preparations and the 
presence of contaminating kinase activities were not systematically 
addressed. In order to circumvent these problems and the variance 
that could result from the differences in the purification strategies, 
we designed a uniform procedure for the purification of 
recombinant CDK7, CDK8 and CDK9 complexes. Using these 
recombinant kinases, we identified additional differences in the 
preference of these kinases towards different parts of the pol II 
CTD (14). In this manuscript, we provide extensive details on the 
expression/purification protocols for the three recombinant kinases 
that will be of use in future attempts to prepare these as well as 
other cyclin-dependent kinases. 
 
MATERIALS AND METHODS 
 
Expression vectors 
 
a. Baculovirus for the expression of His6-CDK8 
 
The GibcoBRL Bac-to-Bac baculovirus expression system was 
used to generate recombinant baculovirus for the expression of 
His6-CDK8. The human CDK8 coding sequence was PCR 
amplified from pBSCDK8 (a gift from E. Lees) using primers for 
the T7 promoter and the C-terminus of CDK8 (5’-GCC GAA 
TTC GAC TAT GAC TTT AAA GTG AAG CTG AGC-3’) and 
sub-cloned into the donor plasmid pFastBacHTa (Invitrogen). 
To generate the desired recombinant baculovirus, the donor 
plasmid (pFastBacHTa/CDK8) was transformed into 
DH10BAC cells, which contain the bacmid (Bmon14272, 
Invitrogen). Recombinant bacmids were isolated from the blue 
colonies and the presence of the coding sequence of CDK8 was 
confirmed by PCR. A bacmid containing the His6-CDK8 
sequence was transfected into Spodoptera frugiperda (Sf9) cells using 
cellfectin. The baculoviruses were amplified and used for protein 
expression.   
 
b. Baculovirus expressing His6-CDK9/CycT1 
 
Recombinant baculovirus for the expression of His6-
CDK9/CycT1 was produced using the Novagen Baculovirus 
expression system. This system utilizes a Bacvector-3000 
(Novagen) triple cut virus DNA, which is a modified form of the 
AcNPV genome. A transfer plasmid cassettes for the expression 
of His6-CDK9 and CycT1 (pBAC-CDK9/CycT1, a gift from D. 
Price (15)) and Bacvector-3000 DNA were co-transfected into 
Sf9 cells. The recombinant baculovirus was amplified and used 
for protein expression. 
 
c. Baculovirus expressing His6-CycH 
 
The coding sequence of human CycH (from pBS/CycH, a gift 
from D. Morgan) was subcloned into pBlueBac2 (Invitrogen). 
The plasmid and the transfection module B825-03 (digested 
AcNPV DNA, Invitrogen) were co-transfected into Sf9 cells. 
Purification of blue plaques (containing recombinant virus) was 
conducted as in reference (16). The presence of the CycH 
encoding sequence was confirmed by Northern blot. 
 
The baculoviruses for the expression of CDK7 and MAT1 were 
gifts from D. Morgan (17). The baculovirus for the expression of 
human CycC was provided by Dr. E. Lees (5).  
 
Growth and maintenance of Sf9 cells 
 
Sf9 cells were cultured at 28°C in tissue culture flasks (175 cm2, 
SARSTEDT) in Grace’s Medium/1X yeastolate solution/1X 
lactalbumin hydrolysate solution/1X antibiotic/antimycotic 
solution (GibcoBRL), and 10% fetal bovine serum (Cansera). 
 
Amplification of recombinant viruses 
 
High titer viral stocks for the production of recombinant proteins 
were prepared from low passage (1 or 2) viral stocks by a two-
step amplification procedure. Sf9 cells at density of 0.1-0.3x106 
cells/ml were infected with individual viruses at a multiplicity of 
infection (MOI) of 0.1-1. The infected cells were incubated for 5-
6 days. The efficiency of infection was monitored by the loss of 
adherence and the larger size of the cells. The supernatant from 
these cultures was used to infect a larger Sf9 culture of density 
0.5-1x106 cells/ml at a MOI of 1. The culture was incubated for 
4-5 days, cells were spun and the supernatant was immediately 
used or stored at -80°C for up to six months. This procedure 
typically produced viral stocks of ~1x108 pfu/ml. 
 
Expression of recombinant kinases 
 
Expression of recombinant CDK complexes was conducted by 
co-infecting about 1.5-2x109 Sf9 cells (1.5-2x106 cells/ml) with 
the appropriate combination of baculoviruses at MOI 4 for each 
individual virus. The cells were harvested after 48 hours by 
spinning at 275 g for 5 minutes at 4ºC, washed with PBS and 
frozen (-80°C) in 15 ml of lysis buffer (10 mM Tris.HCl pH 7.5, 
10 mM NaCl, 2 mM β-mercaptoethanol, 0.5 mM EDTA, 10 mM 
2-glycerophosphate, 0.5 mM Na-vanadate, 2 mM NaF, 2 µg/ml 
leupeptin, 2 µg/ml aprotonin, 2 µg/ml pepstatin, 0.2 % (v/v) 
NP-40, 50 µg/ml PMSF). Alternatively, the cells were 
immediately lysed in lysis buffer by 10 strokes with a Dounce 
homogenizer. After cell lysis, the proteins were extracted by 
adding 0.5M NaCl and 5 mM imidazole, and rocking for 30 min 
at 4ºC. The extract was clarified by spinning in a SW50.1 rotor Pinhero et al.    
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(Beckman) at 75000 g for 30 min and immediately processed by 
metal (Ni2+) affinity chromatography. 
 
Ni2+-NTA pull-down assay 
 
Pull down assays were performed with 250 µl aliquots of Sf9 cell 
extracts and 50 µl of 50% (v/v) Ni2+-NTA agarose beads 
equilibrated with 10 mM Tris.HCl,  pH 7.6, 0.5 M NaCl, 5 mM 
imidazole, 50 µg/ml PMSF and 10% (v/v) glycerol (buffer A). 
The suspension was rocked on a nutator for 1 h and the beads 
were pelleted by spinning for 1 minute at 3000 rpm.  The beads 
were then washed five times with 1ml of buffer A + 0.1M NaCl, 
boiled for 5 minutes in SDS-sample buffer and further analyzed 
by Western blot or silver staining. 
 
Purification of CDK complexes by Ni2+-NTA 
chromatography 
 
The cell extract from about 1 liter of infected cells was mixed 
with 1ml of Ni2+-NTA agarose beads (Qiagen) that were 
equilibrated with 10 mM Tris.HCl pH 7.6, 0.5 M NaCl, 5 mM 
imidazole, 50 µg/ml PMSF and 10% (v/v) glycerol, and rocked 
on a nutator for 1 h. The beads were washed once in the 
equilibration buffer and transferred to a disposable 10 ml column 
(Amersham). Bound proteins were step-wise eluted with 15, 25, 
100 and 400 mM imidazole in 10 mM Tris-HCl pH 7.6, 0.1 M 
NaCl, 50 µg/ml PMSF and 10% (v/v) glycerol. The fractions 
containing the recombinant protein kinases were identified by 
SDS-PAGE/Coomassie Brilliant Blue R-250 staining, pooled and 
stored at -80°C. 
 
Purification of CDK complexes by Mono S 
chromatography 
 
The pooled protein fractions from Ni2+-NTA chromatography 
were buffer exchanged in PD10 columns (Amersham) to 25 mM 
HEPES pH 7.6, 0.1 mM EDTA, 1 mM DTT, 5% (v/v) glycerol, 
50 µg/ml PMSF and 80 mM NaCl. The proteins were loaded on 
a tandem of two 5 ml Econo-Pac Mono S cartridges (BioRad) 
and eluted with a linear 0.08-0.5M NaCl gradient in 25mM 
HEPES pH 7.6, 0.1 mM EDTA, 1 mM DTT, 50 µg/ml PMSF, 
and 5% (v/v) glycerol. The fractions containing recombinant 
protein kinases were identified by SDS-PAGE/silver staining and 
stored at -80ºC. 
 
Kinase substrates 
 
Glutathione-S-transferase carboxyl terminal domain (GST-CTD) 
was expressed and purified as described (18). Highly purified 
myelin basic protein (MBP) from bovine brain was a gift from 
Dr. G. Harauz. 
 
Kinase assays 
 
The kinase assays were performed in a volume of 20 µl 
containing 20 mM Tris.HCl, pH 8, 50 mM KCl, 7 mM MgCl2, 5 
mM 2-glycerophosphate, 100 µg/ml BSA (2µg), 10 µM ATP, 2 
µCi (7.4 x 104 Bq) α-32P-ATP (ICN), 40µg/ml (800 ng) GST-
CTD or MBP and about 100-400 ng/ml (2-8 ng) of purified 
kinase. These amounts correspond to 100-500 fold molar excess 
of substrate versus kinase. It is important to note that the GST-
CTD molecule has at least 52 sites of phosphorylation (52 repeats 
with a consensus YSPTSPS) on a single molecule, thus 
additionally increasing the kinase/substrate ratio. MBP also 
contains multiple sites of phosphorylation. Under the described 
conditions the kinase reactions are linear for at least three hours 
(data not shown). The kinase reactions were incubated for 30 
minutes at 30ºC and terminated by the addition of SDS-PAGE 
loading buffer and then boiled for 5 minutes. Aliquots were 
analyzed by SDS-PAGE gels and autoradiography. The 
incorporation of ATP in GST-CTD (1-52) and MBP (pmol of 
ATP/min/mg of protein) was determined according to the 
procedure in (19). Kinase assays were also performed in the 
presence of kinase inhibitors, DRB (5,6-dichlorobenzimidazole 
riboside), and roscovitine (2-(1-ethyl-2-hydroxyethylamino)-6-
benzylamino-9-isopropylpurine). DRB was dissolved at 50 mM in 
95% ethanol and stored at -20°C. Working dilutions of 800, 200 
and 40 µM in water were prepared at the time of assay and 
immediately added to the kinase reaction. Roscovitine was 
dissolved in DMSO at 50 mM and stored at -20°C. Dilutions in 
water were made prior to the reactions and immediately added to 
the kinase reaction. 
 
RESULTS AND DISCUSSION 
 
Expression of recombinant CDK kinases  
 
We produced recombinant CDK7/His6-CycH/MAT1, His6-
CDK8/CycC and His6-CDK9/CycT1 complexes by co-infecting 
Sf9 cells with the appropriate combination of baculoviruses. Each 
virus was applied at MOI of 4. Preliminary experiments have 
shown that this MOI generates the highest level of expression for 
all the CDKs and that further increase in MOI did not yield more 
protein. The expression of the different subunits of the CDK 
complexes was verified by Western blot with antibodies against 
CDK7, CycH, MAT1, CDK8, CycC and CDK9. These westerns 
were not quantitative and do not necessarily mean that all 
peptides were expressed at similar levels. 
 
Monolayer Sf9 cells in large T-flasks were infected at high density 
(1.5-2x106 cells/ml). We found that this high cell density did not 
lead to poorer expression or protein degradation as compared to 
infection at lower cell density (0.5-1 x106 cells/ml). Considering 
the high cost of growth medium, this approach is more 
economical. We have not tested if the same trend applies to 
infecting Sf9 cells that are maintained in suspension. 
 
An important consideration derived from the Western blot 
analyses was the choice of individual expression of the CDKs 
and cyclins and their subsequent reconstitution in vitro versus co-
expression and assembly in vivo. Both approaches were applied in 
the past (4, 5, 18, 20-22). Although the Westerns blot analyses 
were not quantitative, we noticed that a higher level of expression 
of individual peptides was achieved by co-infection as compared Pinhero et al.    
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to infection with individual viruses. These observations suggest 
that complex formation in vivo stabilizes the individual peptides 
and increases the yields of recombinant proteins. Therefore, we 
recommend that the production of these kinase complexes is 
carried out by co-infection rather than individual expression and 
mixing of the extracts in vitro. It is also important to mention that 
the mixing of the extracts in vitro poses the risk of inadequate 
modifications of the individual peptides in vivo that might lead to 
altered properties of the reconstituted kinases (18, 20). 
 
Confirmation of complex formation by Ni2+-NTA 
pull-down assay 
 
We confirmed the formation of complexes between the 
recombinant proteins by Ni2+-NTA pull-down assay. Cell 
extracts were incubated with Ni 2+-NTA beads and the retained 
proteins were analyzed by Western blot (Fig. 1A). The results 
showed that His6-CycH pulls down CDK7 and MAT1, His6-
CDK8 pulls down CycC and His6-CDK9 pulls down CycT1 (Fig. 
1A). 
 
Fig. 1: Expression and assembly of CDK complexes in Sf9 cells. A: Pull 
down assays were performed with 250 µl Sf9 cell lysates and 25 µl Ni2+-NTA 
agarose beads. The proteins were separated on 10% SDS gels, transferred to 
PVDF membrane and detected by Western blot with antibodies against the 
polypeptides shown on the left. B: Proteins from the pull down assay was 
separated on a 10% gel. Silver stained gel is shown. A prominent band of about 
87 kDa most likely corresponds to CycT1, whereas the 43 kDa corresponds to 
His6-CDK9. 
 
Antibodies against CycT1 were not available. However, a 
prominent band of about 87 kDa most likely corresponding to 
CycT1 was detected in Ni2+-NTA pull-down fractions from His6-
CDK9/CycT1 infected cells by silver staining (Fig. 1B). Thus, the 
recombinant proteins form complexes in vivo. Another important 
conclusion from the image in Fig. 1B is that the pull-down 
fractions are unclean and should be used only for confirmation 
of expression and complex formation, but not for fine analyses. 
Purification of CDK complexes by Ni2+-NTA 
chromatography 
 
All the CDK complexes were uniformly purified by a two-step 
process involving Ni2+-NTA agarose chromatography followed 
by Mono S chromatography (Fig. 2). 
 
 
Fig. 2: A strategy for the purification of CDK complexes. Sf9 cells were co-
infected with the baculoviruses expressing cyclin dependent kinases and their 
corresponding cyclin partners. Cell extract was loaded on Ni2+-NTA beads and 
eluted with stepwise imidazole gradients. Fractions containing the recombinant 
kinases were pooled, buffer exchanged on PD10 column and loaded on Mono S 
beads and purified by a linear 0.08-0.5 M NaCl gradient. 
 
During  Ni2+-NTA chromatography, CDK7/His6-CycH/MAT1 
complexes were eluted at a low imidazole concentration of 25 
mM (Fig. 3A), whereas His6-CDK8/CycC and His6-
CDK9/CycT1 were eluted at higher imidazole concentrations of 
100 and 400 mM, respectively (Figs. 3B and C). At this stage, the 
fractions containing different recombinant kinases were 
contaminated with different sets of peptides that in certain cases 
contributed to estimated 40% of the total protein. We did not 
investigate the nature of these proteins. Also, we detected a very 
significant CTD kinase activity in crude extracts and in the Ni2+-
NTA fractions from the uninfected cell extracts, which precludes 
the quick and reliable detection of the expression of the kinases 
by kinase assays. This observation also indicates that the Ni2+-
NTA fractioned kinases are inappropriate for analysis of their 
kinase activity or other fine assays. This necessitated further Pinhero et al.    
 
 
Biological Procedures Online • Vol. 6 No. 1 • August 18, 2004 • www.biologicalprocedures.com 
167
purification by ion exchange chromatography to remove the 
contaminating proteins. 
 
F i g .  3 :  P u r i f i c a t i o n  o f  C D K  c o m p l e x e s  b y  N i 2+-NTA agarose 
chromatography. A: CDK7/His6-CycH/MAT1; B: His6-CDK8/CycC; C: His6-
CDK9/CycT1; D: Proteins from uninfected Sf9 cells. Coomassie stained gels 
with different fractions from the Ni2+-NTA agarose chromatography of cell 
extracts are shown. Molecular weight markers are shown on the left. The bands 
corresponding to the kinases and the cyclin partners are shown on the right. L, 
load. The concentration of imidazole in the corresponding fractions is shown on 
the top of the figure. 
 
Purification of CDK complexes by Mono S 
chromatography 
 
All the fractions from the Ni2+-NTA agarose chromatography 
that contained the CDK complexes of interest were pooled and 
purified by Mono S chromatography. This additional step 
produced significantly cleaner CDK complexes (Figs. 4A, B and 
C). 
 
In the case of CDK7/His6-CycH/MAT1, a peak consisting of 
two bands with molecular weights of approximately 40 and 36 
kDa was eluted at a low salt concentration of around 100 mM 
NaCl (Fig. 4A, lanes 1-9). Western blot analyses (not shown) 
indicated that the 40 kDa band is a doublet of CDK7 and His6-
CycH, while the 36 kDa corresponds to MAT1. It should be 
noted that the peak was followed by a trail of the 40 kDa band 
that appeared to possess the CDK7/His6-CycH doublet but lack 
the MAT1 band (Fig. 4A, lanes 10-15). Our results suggest that 
besides the tripartite CDK7/His6-CycH/MAT1 complex, a 
bipartite CDK7/His6-CycH complex and possibly monomeric 
His6-CycH were purified during the Ni2+-NTA agarose step. 
Earlier reports have established that the tripartite and bipartite 
complexes differ in their substrate specificity (18, 20). Thus, the 
Mono S purification step is necessary not only to exclude the 
contaminating peptides from the Ni2+-NTA agarose step, but 
also to resolve these two complexes. 
 
Fig. 4: Purification of CDK complexes from pooled Ni2+-NTA fractions by 
Mono S chromatography. A linear gradient of 80-500 NaCl was applied. The 
100-460 mM range of the gradient is shown. A: CDK7/His6-CycH/MAT1; B: 
His6-CDK8/CycC; C: His6-CDK9/CycT1. Silver stained gels with different 
fractions are shown. Molecular weight markers are shown on the left. The bands 
corresponding to the kinases and the cyclin partners are shown on the right. L, 
load. 
 
His6-CDK8/CycC (Fig. 4B, lanes 12-21) and His6-CDK9/CycT1 
(Fig. 4C, lanes 15-23) were eluted at higher salt concentrations 
from the Mono S column. His6-CDK8, CycC and His6-CDK9 
were estimated to be approximately 53, 36 and 43 kDa, 
respectively by Western blot analyses (data not shown). The peak 
of His6-CDK8/CycC (Fig. 4B, lanes 12-17) was followed by a 
trail of fractions containing His6-CDK8 only (Fig. 4B, lanes 19-
22). In the case of His6-CDK9/CycT1, the peak containing the 
complex (Fig. 4C, lanes 19-23) was preceded by fractions that 
contained predominantly His6-CDK9 (Fig. 3C, lanes 15-18). 
Again, the profile of peptides in the Mono S chromatography 
fractions clearly indicates that the affinity chromatography step 
purifies a mixture of assembled complexes and monomeric 
tagged polypeptides. This observation should be considered if the 
properties of the monomeric subunits versus the assembled 
complex are to be analyzed. 
 
Recovery of recombinant CDKs 
 
We estimate that, on an average, from 1 liter culture of infected 
Sf9 cells, we purified about 115 µg, 880 µg and 1.2 mg of pure Pinhero et al.    
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CDK7/His6-CycH/MAT1, His6-CDK8/CycC and His6-
CDK9/CycT1 respectively. We suspect that the lower yield of 
CDK7/ His6-CycH/MAT1 is stemming from its poorer affinity 
towards Ni2+-NTA agarose as exemplified by its elution at lower 
imidazole concentration (Fig. 3A). 
 
Activity of the kinases 
 
Fig. 5: Phosphorylation of GST-CTD and MBP by CDK7/His6-
CycH/MAT1, His6-CDK8/CycC and His6-CDK9/CycT1. Lanes 1, 4, and 7 
are kinases without any substrate. CDK8 and CDK9 have background bands that 
resulted from their autophosphorylation. CDK7 produced two bands with GST-
CTD, the low mobility band corresponds to the hyperphosphorylated form (IIo), 
and the higher mobility band, the hypophosphorylated IIa. CDK8 and CDK9 
produced only the IIa form. 
 
The functional activities of the purified kinases were studied 
using GST-CTD and MBP as substrates ((14) and Fig. 5)). All the 
kinases phosphorylated GST-CTD and MBP (Fig. 5). 
CDK7/His6-CycH/MAT1 transferred 1.6 and 0.94 nmols of 
ATP/min/mg protein with GST-CTD and MBP as substrates, 
respectively. The His6-CDK8/CycC preparations showed 
somewhat lower specific activities of 0.1 and 0.15 nmols of 
ATP/min/mg protein with GST-CTD and MBP, whereas the 
specific activities for His6-CDK9/CycT1 were 0.38 and 3.74 
nmols of ATP/min/mg protein. No kinase activity was detected 
in the corresponding fractions from non-infected Sf9 cell. 
Importantly, the purified kinases displayed distinct patterns of 
CTD phosphorylation, which were reported elsewhere (14). 
 
As reported by others, roscovitine is a potent inhibitor of CDK7 
and CDK9, but not CDK8 (23-25), whereas DRB inhibits CDK9 
at lower concentrations as compared to CDK7 (26). We used this 
information and performed several experiments to confirm the 
catalytical purity of the kinases. I n  F i g .  6 ,  w e  s h o w  t h a t ,  i n  
agreement with the literature, roscovitine strongly inhibits 
CDK7/His6-CycH/MAT1 (Fig. 6, upper panel, lanes 1-5), but 
not His6-CDK8/CycC (Fig. 6, upper panel, lanes 6-10). In 
addition, we also show that His6-CDK9/CycT1 (Fig. 6, upper 
panel, lanes 11-15) is equally sensitive to roscovitine as compared 
to CDK7/His6-CycH/MAT1 (Fig. 6, upper panel, lanes 1-5, see 
also the graph in the lower panel of the figure). DRB is a potent 
inhibitor of His6-CDK9/CycT1 (Fig. 6, lower panel, lanes 11-15) 
and a moderate inhibitor of CDK7/His6-CycH/MAT1 (Fig. 6, 
lower panel, lanes 1-5). His6-CDK8/CycC showed intermediate 
sensitivity to DRB (Fig. 6, lower panel, lanes 6-10). Together, this 
data shows the expected inhibition patterns of these kinases with 
two independent kinase inhibitors thus supporting the notion of 
their catalytic purity. 
 
Fig. 6: Effect of roscovitine and DRB on the phosphorylation of GST-CTD 
by CDK7/His6-CycH/MAT1, His6-CDK8/CycC and His6-CDK9/CycT1. 
Roscovitine and DRB were added to the kinase reaction mixtures at 
concentrations indicated and kinase reactions were carried out as described in 
Materials and Methods. Lanes 1, 6 and 11 are kinases without substrate. The 
graph shows the percentage of the kinase activity as compared to their 
corresponding activity without inhibitors. 
 
Significance and novelty of the proposed 
purification procedure 
 
The significance of this uniform procedure is rationalized as 
follows. When CDK complexes are obtained by different 
expression/purification methods, there is a real risk for the 
introduction of contaminating kinases and other peptides. 
Consequently, the comparison of such complexes can be 
impaired by the nature of the impurities. This concern is 
especially valid when working with immunoprecipitated 
complexes, which may contain other kinases that are difficult to 
track. If the immunoprecipitates are derived from crude extracts, 
it is also possible that the experiment will be conducted with 
multiple forms of these complexes that share the same CDK 
component (see (2) for reference). Pinhero et al.    
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Many of the studies that have characterized CDK7, CDK8 and 
CDK9 have used either immunoprecipitated enzyme complexes 
(4, 27-29) or different methods for purification of different 
kinases (4, 5, 18, 20, 30). In order to achieve a high precision in 
the comparison of the three CDK complexes, we expressed and 
purified them by a uniform procedure. This procedure generates 
large amounts of kinases that are practically devoid of other 
kinase activities. It is important that this procedure enabled us to 
identify distinct preferences of CDK7, CDK8 and CDK9 
towards different parts of pol II CTD (14). This analysis is 
demanding. The CTD consists of 52 repeats of a Ser/Thr-rich 
consensus heptapeptide (2) which might attract promiscuous 
kinase activities. We believe that our success in these analyses 
demonstrates the high value of the proposed procedure. 
 
We did not detect measurable CTD kinase activities in the 
corresponding fractions from uninfected cells, meaning that our 
preparations are not contaminated with independent co-purifying 
CTD kinase activities. At the same time, we observed different 
patterns of contaminating peptides in the preparations of CDK7, 
CDK8, and CDK9. Our interpretation is that these peptides co-
purified probably because of interactions with the complexes. We 
are not sure how these peptides contributed to the activity and 
specificity of each kinase. The inhibitory studies with roscovitine 
and DRB (see Fig. 6) and juglone (14) suggest that most if not all 
of the CTD kinase activities should be attributed to the 
recombinant kinases. However, we can not exclude the 
possibility that minor amounts of very active contaminating 
kinases could alter the results with other substrates. We 
recommend that a set of inhibitory studies is preformed with 
each substrate to minimize these risks. 
 
A similar, but not identical procedure for the purification of His-
CDK9/CycT1 was used in an earlier study (15). The procedures 
for the purification of His6-CDK8/CycC and CDK7/His6-
CycH/MAT1 are novel. 
 
We believe that our systematic approach can be applied 
effectively to characterize other CDKs. In addition, we believe 
that the presented details on the purification of the three CDKs 
can be of use when other finer analyses of CDK7, CDK8 and 
CDK9 are conducted. 
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PROTOCOLS 
 
Amplification of baculovirus stocks 
 
1.  Infect 10 ml Sf9 insect culture in a 25 cm2 T-flask (SARSTEDT) at a density of 0.1-0.3x106 cells/ml with 0.1 ml of virus stock 
passage 1 or passage 2 (MOI 0.1-1.). 
2.  Incubate the cells for 5-6 days at 28°C. We consider that 100% infection is achieved when all the cells are detached from the 
substrate. Normally, 100% of the infection is observed by day 4. 
3.  Pellet the cells by spinning at 275xg for 5 minutes and collect the supernatant. 
4.  Use 1 ml of this supernatant to infect a large culture of 75 ml at a density of 0.5-1x106 cells/ml in a 175 cm2 flask (SARSTEDT). 
Incubate the cells for 4-5 days and collect the supernatant.  
5.  Use the supernatant from step 4 for infecting the Sf9 culture for large scale protein expression. The stocks can be stored at 4°C for 
a week or -80°C for up to six months. These stocks (Passage 4) typically contain about 1x108 pfu/ml. 
 
Infecting and harvesting insect cells 
 
1.  Grow Sf9 cells to a density of 1.5-2x106 cells/ml in several (5-8) 175 cm2 T-flasks. 
2.  Infect each flask with 2 ml of passage 4 of each of the appropriate viruses and incubate for 48 hours at 28°C. Check the cells for 
infection under microscope. 100% infection (large floating cells) should be observed 30 hours post infection.  
3.  Harvest the cells after 48 hours by spinning at 275x g for 5 minutes at 4°C. 
4.  Pour off the supernatant, loosen the pellet by gently shaking it and wash the pellets with 15 ml of phosphate buffered saline. 
5.  Add approximately 3 pellet volumes of Lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 2 mM β-merkaptoethanol, 0.5 mM EDTA, 
10 mM 2-glycerophosphate, 0.5 mM Na vanadate, 2 mM NaF, 2 µg/ml leupeptin, 2 µg/ml aprotonin, 2 µg/ml pepstatin, 0.2% 
NP-40, 50 µg/ml PMSF) and freeze at -80°C. 
 
Preparation of cell lysate 
 
1.  Thaw the re-suspended cells in an ice bath by gently swirling the tube. Add fresh PMSF.  
2.  Leave the lysate on ice for 10 minutes. 
3.  Pass the lysate through a dounce homogenizer 10 times. Check for cell lysis under a microscope. 
4.  Add imidazole and NaCl to a final concentration of 5 mM and 0.5 M, respectively. 
5.  Rock the lysate for 30 minutes in the cold room. 
6.  Spin at 75000 x g at 4ºC in SW50.1 rotor (Beckman) for 30 minutes. 
7.  Transfer the supernatant to a fresh pre-chilled tube; add glycerol and MgCl2 to a final concentration of 10% and 3 mM, 
respectively. 
 
Note: You can freeze the sample at this point. If planning to load to the N2+-NTA agarose column on the same day, do not add 
glycerol. 
 
Ni2+-NTA chromatography 
 
1.  Equilibrate 1 ml Ni2+-NTA agarose beads (Qiagen) with 10 ml of buffer A (10 mM Tris-HCl pH 7.6, 0.5 M NaCl, 5 mM imidazole, 
50 µg/ml PMSF, 10% glycerol) in a 50 ml falcon tube. 
2.  Spin the beads at 3000 rpm for 2 minutes in a table-top centrifuge and aspire the supernatant. 
3.  Add the cell extract from 1 liter of infected cells. Rock the tube for 1 h in the cold room. 
4.  Pellet the beads at 3000 rpm for 2 minutes in a table-top centrifuge, collect the supernatant (flow through) by aspiration, and store 
at -80°C. If there is any problem with binding, the supernatant can be used again.  
5.  Add 10 ml buffer A to the beads and transfer to a 15 ml disposable BioRad column.  
6.  Wash the column with 10 ml buffer A + 0.1 M NaCl in the cold room. 
7.  Elute the proteins as 5 x 1ml fractions in steps using 
a.  10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 µg/ml PMSF, 10% glycerol and 15 mM imidazole. 
b.  10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 µg/ml PMSF, 10% glycerol and 25 mM imidazole. 
c.  10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 µg/ml PMSF, 10% glycerol and 100 mM imidazole. Pinhero et al.    
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d.  10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 µg/ml PMSF, 10% glycerol and 400 mM imidazole. 
8. Run samples of the fractions on SDS-PAGE and stain with Coomassie Brilliant Blue. Pool the fractions containing the proteins of 
interest and store at -80°C. 
 
Mono S chromatography 
 
1.  Equilibrate a PD10 column (Amersham Pharmacia Biotech) with 25 ml of 25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 
0.08M NaCl, 1 mM DTT, 50 µg/ml PMSF. 
2.  Buffer exchange the pooled fractions from the Ni2+-NTA chromatography step as per manufacturer’s instruction. 
3.  Attach two 5 ml Econo-Pac Mono S cartridges (BioRad) in tandem and equilibrate as follows:  
a.  5 ml of buffer A (25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, 50 µg/ml PMSF) at 0.5 ml/min. 
b.  5 ml of buffer A at 1ml/min. 
c.  10 ml of 1M NaCl in buffer A. 
d.  5 ml of gradient 1M - 80 mM NaCl in buffer A at 1 ml/min. 
e.  15 ml of 80 mM NaCl in buffer A.  
4.  Load the column at 1ml/min and collect the flow through and save. 
5.  Wash the column with 5 ml of 80 mM NaCl in buffer A at 1 ml/min. 
6.  Elute with a linear gradient of 20 ml of 80-500 mM NaCl in buffer A at 1 ml/min. 
7.  Collect 1 ml fractions in 1.5 ml tubes containing 100 µl of 80% glycerol. 
8.  Analyze the samples of the fractions by SDS-PAGE and silver staining. Pool the fractions of interest and store at -80°C. 
 
Equipment 
 
1.  Tissue culture hood 
2.  Basic radiation safety equipment and Geiger counter 
3.  Ultracentrifuge, centrifuge (Beckman) 
4.  Mini-PROTEAN II electrophoresis cell (BioRad) 
5.  Microcentrifuge, incubator, standard Molecular Biology equipments, gel dryer 